Goldman Sachs
BOLT icon

Goldman Sachs’s Bolt Biotherapeutics BOLT Stock Holding History

Goldman Sachs’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,501
Closed -$26.8K – 6082
2024
Q4 		$26.8K Buy
+2,501
New +$30.2K ﹤0.01% 5880
2023
Q3 		– Sell
-14,209
Closed -$364K – 5556
2023
Q2 		$364K Buy
14,209
+55
+0.4% +$1.75K ﹤0.01% 4910
2023
Q1 		$393K Buy
14,154
+3
+0% +$88 ﹤0.01% 4965
2022
Q4 		$368K Buy
14,151
+13,544
+2,231% +$371K ﹤0.01% 5037
2022
Q3 		$18K Sell
607
-1,081
-64% -$44.7K ﹤0.01% 5955
2022
Q2 		$69K Sell
1,688
-626
-27% -$24.3K ﹤0.01% 5958
2022
Q1 		$126K Sell
2,314
-21,681
-90% -$1.46M ﹤0.01% 6033
2021
Q4 		$2.35M Buy
23,995
+1,857
+8% +$352K ﹤0.01% 4120
2021
Q3 		$5.6M Buy
22,138
+52
+0.2% +$14.7K ﹤0.01% 3262
2021
Q2 		$6.83M Buy
22,086
+10,662
+93% +$4.33M ﹤0.01% 3063
2021
Q1 		$7.52M Buy
+11,424
New +$7.43M ﹤0.01% 2800

Other funds holding BOLT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's BOLT Position: Q1 2025 in Review

Goldman Sachs sold out of Bolt Biotherapeutics (BOLT) in Q1 2025, closing a stake of 2,501 shares — an estimated $26.8K sold.

Goldman Sachs first reported a position in BOLT in Q1 2021 and held it in 11 quarters. The position peaked at $7.52M in Q1 2021. 29 funds tracked by Wall St. Rank hold BOLT as of Q1 2025.

  • Goldman Sachs reported no remaining Bolt Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Goldman Sachs sold 2,501 Bolt Biotherapeutics shares in Q1 2025, an estimated $26.8K.
  • Goldman Sachs first reported a position in Bolt Biotherapeutics in Q1 2021 and held it in 11 quarters.
  • Goldman Sachs's Bolt Biotherapeutics position peaked at $7.52M in Q1 2021.
  • 29 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q1 2025.

Based on Goldman Sachs's 13F filing for Q1 2025, filed 9 May 2025.